Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance
H Tanaka, E Kono, CP Tran, H Miyazaki, J Yamashiro… - Nature medicine, 2010 - nature.com
The transition from androgen-dependent to castration-resistant prostate cancer (CRPC) is a
lethal event of uncertain molecular etiology. Comparing gene expression in isogenic …
lethal event of uncertain molecular etiology. Comparing gene expression in isogenic …
RSK in tumorigenesis: connections to steroid signaling
TSK Eisinger-Mathason, J Andrade, DA Lannigan - Steroids, 2010 - Elsevier
The Ser/Thr kinase family, RSK, has been implicated in numerous types of hormone-
dependent and-independent cancers. However, there has been little consideration of RSKs …
dependent and-independent cancers. However, there has been little consideration of RSKs …
[HTML][HTML] Paxillin regulates androgen-and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells
A Sen, K O'Malley, Z Wang, GV Raj… - Journal of Biological …, 2010 - ASBMB
Although transcriptional effects of androgens have been extensively studied, mechanisms
regulating transcription-independent (nongenomic) androgen actions are poorly …
regulating transcription-independent (nongenomic) androgen actions are poorly …
Hormonal therapy for prostate cancer: current topics and future perspectives
H Suzuki, S Hinotsu, H Akaza… - … journal of urology, 2010 - okayama.elsevierpure.com
Hormonal therapy for prostate cancer: Current topics and future perspectives: Editorial — 岡山
大学 メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ 岡山大学 ホーム …
大学 メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ 岡山大学 ホーム …
Effects of androgen ablation therapy in TRAIL death ligand and its receptors expression in advanced prostate cancer
Background: It is not known whether androgen ablation therapy (AAT) influences TRAIL
death ligand and its receptors expression of prostate cancer (PCa) cells. Aim: To investigate …
death ligand and its receptors expression of prostate cancer (PCa) cells. Aim: To investigate …
E6-AP 在前列腺癌LNCaP 细胞基因表达调控中的作用
杜培革， 韩笑， 梁骥， 李贺， 安丽萍， 徐广宇… - 吉林大学学报(医学版 …, 2010 - cqvip.com
目的: 探讨前列腺癌LNCaP 细胞中E6 相关蛋白(E6-AP) 对雄激素受体(AR)
和丝苏氨酸激酶(Akt) 表达的调节作用, 阐明E6-AP 的作用机制. 方法: 应用双稳定表达的人 …
和丝苏氨酸激酶(Akt) 表达的调节作用, 阐明E6-AP 的作用机制. 方法: 应用双稳定表达的人 …
[PDF][PDF] Genetické riziko karcinomu prostaty
M Král, V Vyhnánková, V Študent, J Bouchal - Česká urologie, 2010 - czechurol.cz
Král M, Vyhnánková V, Študent V, Bouchal J. Genetic risk of prostate cancer Prostate cancer
is a disease which origin is affected appart from enviromental factors also by genetic factors …
is a disease which origin is affected appart from enviromental factors also by genetic factors …
Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model
Aim To construct tissue microarrays (TMAs) that consisted of prostate tumours from the
transgenic adenocarcinoma of mouse prostate (TRAMP) mice and non-transgenic murine …
transgenic adenocarcinoma of mouse prostate (TRAMP) mice and non-transgenic murine …
Second-Line Antiandrogen Therapy in Japanese Men with Advanced Prostate Cancer Relapsed after Primary Combined Androgen Blockade: Who Will Benefit from …
M Kobayashi, K Suzuki, S Kurokawa, M Yuzawa… - Urologia …, 2010 - karger.com
Objectives: To identify patients who benefit from the salvage hormonal therapy in men with
advanced prostate cancer who relapsed after primary hormonal therapy. Patients and …
advanced prostate cancer who relapsed after primary hormonal therapy. Patients and …
EGF-Mediated Regulation of EGR1 in Prostate Cancer Cells
JL Gregg - 2010 - rave.ohiolink.edu
Prostate tumorigenesis is a complex and multi-faceted process. To examine differential
expression between tumor and normal prostate samples, paired tumor and non-neoplastic …
expression between tumor and normal prostate samples, paired tumor and non-neoplastic …